Broad Spectrum CBD Distillate

The Endocannabinoid System (ECS) is a complex cell-signaling system identified in the early 1990s by researchers exploring THC, a well-known cannabinoid. While the ECS is affected by THC, it's crucial to understand how another major cannabinoid, CBD (cannabidiol), interacts with it.

Key Components of the ECS:

• Endocannabinoids: These are naturally produced compounds in the body that are similar to cannabinoids. The two major endocannabinoids are anandamide and 2-arachidonoylglycerol (2-AG).
• Receptors: Found throughout the body, these are the sites where endocannabinoids and cannabinoids can bind. The two primary ECS receptors are CB1 receptors (mainly in the brain) and CB2 receptors (commonly found in the immune system).
• Enzymes: These break down endocannabinoids once they've carried out their function. Two main enzymes are fatty acid amide hydrolase, which breaks down anandamide, and monoacylglycerol acid lipase, which breaks down 2-AG.

How CBD Interacts with the ECS:

• Receptor Activity: Unlike THC, which directly binds to CB1 receptors, CBD doesn't bind strongly to either CB1 or CB2 receptors. Instead, it is believed to modulate receptor activity, possibly by influencing the shape of the receptor or altering the ability of other compounds to bind to them. This might be a reason why CBD doesn't produce the "high" associated with THC.
• Endocannabinoid Breakdown: CBD can inhibit the breakdown of naturally occurring endocannabinoids, particularly anandamide. By doing so, it potentially increases the concentration of endocannabinoids in the system, amplifying their beneficial effects.
• Enhanced Presence of Endocannabinoids: There's evidence to suggest that CBD can stimulate the ECS to produce more of its own endocannabinoids.
• Additional Interactions: Beyond the ECS, CBD has been found to interact with several other non-endocannabinoid signaling systems, which can contribute to its therapeutic effects.